Security record · archived quarter
AKRO
Akero Therapeutics, Inc. · Healthcare · Biotechnology
8Tracked holders
0Δ holders
15.01MShares held
$430.62MReported value
+1New positions
−1Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +26.1% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
Ownership over time
Who holds it · Q3 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 7.90M | +54.4% | $226.55M | 0.0% | ▲ Add | 2 | SEC ↗ ×7 |
| 2 | T. Rowe Price ✦ | 3.81M | -8.2% | $109.26M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 1.57M | -3.0% | $45.08M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 4 | Point72 Asset Management ✦ | 1.30M | New | $37.39M | 0.1% | New | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 149.90K | -62.1% | $4.30M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 6 | D. E. Shaw & Co. ✦ | 116.38K | -63.1% | $3.34M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 7 | Two Sigma Investments ✦ | 88.82K | -26.0% | $2.55M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Millennium Management ✦ | 74.63K | -56.0% | $2.14M | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $37.39M | 0.1% |
Exited
| Renaissance Technologies | $565,386 | was 0.0% |
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2024 ·
Methodology ·
Get this via the API